Overview

Phase II Exploratory Clinical Study of KUX-1151

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.

Phase:

Phase 2

Details

Lead Sponsor:

Kissei Pharmaceutical Co., Ltd.